Search results
With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio
FierceBiotech· 55 minutes agoSyncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
Clinical Trials Arena via Yahoo Finance· 1 day agoThe safety profile of Truqap in combination with paclitaxel...will further our understanding of the...
Opinion | I Tried to Protect My Mother From Dying in Pain. The Law Robbed Her of That Dignity.
MedPage Today· 4 days agoWhen my mother was 56 years old, she found out that her father had metastatic prostate cancer. The ...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 2 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
America first declared war on cancer half a century ago. Today’s regulatory hurdles won’t help us...
Fortune via Yahoo Finance· 2 days agoExciting new technologies can help the U.S. government win the war that it declared 50 years ago—but...
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
Morningstar· 2 days agoAstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The ...
What do we know about Kate's cancer treatment?
BBC via AOL· 6 days agoHow many people get cancer? In the UK, one in two people develop some kind of cancer during their lifetime. There are more than 200 different types of &...
Study demonstrates how AI can develop more personalized cancer treatment strategies
Medical Xpress· 3 days ago...In a study, titled "Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy" published in Cancer Research, researchers from the University of Oxford and Moffitt Cancer Center in Florida introduce a novel framework that applies deep reinforcement learning, DRL, (a form of AI)...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 2 days agoTuesday, AstraZeneca Plc AZN announced topline data from the CAPItello-290 Phase 3 trial for Truqap...
Xencor shares target cut by BMO on plamotamab rights By Investing.com
Investing.com· 6 days agoThe reacquisition of plamotamab rights by Xencor comes as the market has shown a growing...